Emerald Advisers LLC Has $43.49 Million Holdings in TransMedics Group, Inc. $TMDX

Emerald Advisers LLC decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 11.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 387,588 shares of the company’s stock after selling 51,741 shares during the quarter. TransMedics Group accounts for approximately 1.4% of Emerald Advisers LLC’s holdings, making the stock its 17th largest holding. Emerald Advisers LLC owned 1.14% of TransMedics Group worth $43,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Amalgamated Bank raised its position in TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after buying an additional 80 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of TransMedics Group by 24.5% during the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after acquiring an additional 108 shares in the last quarter. CWM LLC raised its holdings in shares of TransMedics Group by 18.5% in the third quarter. CWM LLC now owns 897 shares of the company’s stock valued at $101,000 after purchasing an additional 140 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of TransMedics Group by 4.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock worth $455,000 after purchasing an additional 142 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $133.81 on Thursday. TransMedics Group, Inc. has a 12-month low of $56.50 and a 12-month high of $156.00. The firm has a market capitalization of $4.57 billion, a price-to-earnings ratio of 54.17 and a beta of 2.03. The stock’s 50 day moving average price is $131.98 and its two-hundred day moving average price is $122.82. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period in the previous year, the firm earned $0.12 EPS. The firm’s revenue was up 32.2% compared to the same quarter last year. On average, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director directly owned 12,134 shares in the company, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Morgan Stanley raised their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Canaccord Genuity Group increased their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Needham & Company LLC boosted their price target on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.